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The use of central venous catheters (CVC) and broad-spectrum antibacterials are among the main risk 
factors for the development of candidemia in patients admitted to intensive care units (ICU). It is known 
that some antibacterials increase the resistance of these yeasts to azole antifungals. Thus, the aim of 
this research was to determine whether yeast present in CVC colonizations previously exposed to cell-
wall targeted antibacterials benefit from a reduction in susceptibility to fluconazole and voriconazole, 
facilitating their ability to form biofilms. Candida albicans, C. tropicalis, C. glabrata, C. parapsilosis and 
C. guilhermondii were seeded into antibacterial (cefepime, meropenem, vancomycin, and piperacillin-
tazobactam) gradient plates produced in Mueller-Hinton Agar. The susceptibility to fluconazole and 
voriconazole and the biofilm formation of the yeasts were tested before and after exposure to the 
antibacterials. None of the antibacterials exerted a significant effect on the in vitro susceptibility of the 
yeasts to the antifungal agents or on their ability to form biofilms. These results suggest that increased 
candidemia in ICU patients is not attributable to possible alterations in the yeasts, but is more likely 
caused by a weakening of the patient’s general condition after long exposure to infection.
Uniterms: Central venous cateter/use. Candidemia/control. Biofilm/formation. Antibacterials. 
Antifungals. Candida/species/control..
O uso de cateter venoso central (CVC) e antibióticos de amplo espectro estão entre os principais fatores 
de risco para o desenvolvimento da candidemia em pacientes internados em unidades de terapia intensiva 
(UTI). É conhecido que alguns antibióticos aumentam a resistência das leveduras aos antifúngicos 
azólicos. Assim, o objetivo deste estudo foi avaliar se leveduras presentes em colonização de CVC 
expostas a antibióticos que atuam em parede celular se beneficiam de uma redução na suscetibilidade 
ao fluconazol e voriconazol e se obtêm maior capacidade de formar biofilme. Candida albicans, C. 
tropicalis, C. glabrata,C. parapsilosis e C. guilhermondii foram semeadas em placas de Mueller-Hinton 
Agar, com gradientes de antibióticos (cefepima, meropenem, vancomicina e piperacilina-tazobactam). 
A suscetibilidade e a formação de biofilme das leveduras foram testadas antes e após a exposição aos 
antibióticos. Nenhum dos antibióticos provocou alterações detectáveis in vitro sobre a suscetibilidade das 
leveduras aos antifúngicos ou à capacidade de formar biofilme. Estes resultados sugerem que o aumento 
da candidemia na UTI não seria atribuído a possíveis alterações provocadas nas leveduras e sim pelo 
enfraquecimento da condição geral do paciente após longa exposição à infecção.
Unitermos: Cateter venoso central/uso. Candidemia/controle. Biofilme/formação. Antibióticos. 
Antifúngicos. Candida/espécies/controle.
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INTRODUCTION
The incidence of candidemia in tertiary public 
hospitals in Brazil is approximately 2.5 cases per 1000 
hospital admissions (Colombo et al., 2013). Candida 
species are the fourth-most-common etiological agent 
of nosocomial bloodstream infections (BSIs), and have 
a mortality rate of over 40%. Risk-factors for invasive 
candidiasis include the use of central venous catheters 
(CVC) and broad-spectrum antibacterials. In one study, 
CVCs were considered the main source of fungemia in 
more than 80% of cases (Lin et al., 2005). A previous study 
conducted at the University Hospital of Maringá found a 
rate of yeast colonization of CVCs of 10.89% (Ramos et 
al., 2011).
Treatment with two or more broad-spectrum 
antibacterials is associated to an imbalance in the 
endogenous flora which enables yeasts to overgrow (Lin 
et al., 2005). Furthermore, some antibacterials are able to 
change the susceptibility profile of yeasts to antifungals by 
over expressing resistant genes (Vogel et al., 2008; Oliver 
et al., 2008) or by increasing their ability to form biofilms 
(McCool et al., 2008).
Protein-synthesis targeted antibacterials, such as 
rifampicin and tetracycline, act on the antifungal activities 
of fluconazole. Rifampicin induces the activation of 
Candida albicans multi drug resistant-1 (MDR1) genes to 
fluconazole (Vogel et al., 2008), while tetracycline alters 
the gene expression of ergosterol biosynthesis increasing 
resistance to fluconazole and terbinafine (Oliver et al., 
2008), while also increases C. albicans virulence, hyphae 
formation and, to a lesser extent, drug efflux and the 
formation of biofilms (McCool et al., 2008).
Since the vast majority of ICU patients have 
CVCs inserted and receive at least one antibacterial 
for prophylaxis or treatment, the overgrowth of yeasts 
is a serious concern which may lead to a worsening of 
their diseases, prolonged hospitalization and increased 
mortality rates (Lin et al., 2005).
The investigations of interactions of the antibacterials 
with the antifungals reported above only cite drugs 
that affect RNA and protein synthesis, rifampicin and 
tetracycline, respectively. However, no studies have 
been carried out with antibacterials that act on cell-wall 
synthesis.
Therefore, the objective of the present study was 
to evaluate, in vitro, whether yeast present in CVC 
colonizations, which have been exposed to antibacterials 
that act on bacterial cell-wall synthesis, undergo alterations 
in their susceptibility to fluconazole and voriconazole and 
in their ability to form biofilms.
MATERIAL AND METHODS
Material
The antibacterials cefepime (Aurobindo Pharma 
Limited), meropenem (Instituto BioChimico Indústria 
Farmacêutica Ltda), piperacillin-tazobactam and 
vancomycin (Novafarma Indústria Farmacêutica Ltda) 
were purchased by the University Hospital of Maringá, 
Brazil, and used in this research with permission. The 
antifungals fluconazole and voriconazole were purchased 
from Sigma Chemical Co.
The working concentrations of the antibacterials 
cefepime (24 mg/L), meropenem (12 mg/L), piperacillin-
tazobactam (192 mg/L) and vancomycin (20 mg/L) 
were established according to their pharmacodynamic 
targets against: Enterobacteria (3 x MIC ≤8 µg/mL 
for cefepime and 3 x MIC≤ 4 µg/mL for meropenem), 
Pseudomonas aeruginosa (4 x MIC≤64/4 µg/mL for 
piperacillin-tazobactam) and Staphylococcus aureus 
(5 x MIC≤4 µg/mL for vancomycin), as established by the 
Clinical and Laboratory Standard Institute (CLSI, 2005), 
Mattoes et al. (2004) and Rybak (2006).
Sampling collection
The study protocol was approved by the Local 
Research Ethics Committee prior to sample collection 
(authorization number 251/07). Five yeasts isolated in a 
previous study (Ramos et al., 2011) were included in this 
evaluation.
Antifungal susceptibility test
The minimal inhibitory concentrations (MIC) of 
fluconazole and voriconazole against the yeasts were 
obtained by broth microdilution according to the Clinical 
and Laboratory Standards Institute (CLSI, 2008). C. 
parapsilosis ATCC 22019 was used as a reference.
Antifungal susceptibility test of yeasts pre-treated 
with antibacterials
The yeasts were pre-treated with antibacterials by 
using a gradient of concentration system on slanted plates 
as described by Szybalski, Bryson (1952). Briefly, bases 
(10 mL) of Mueller-Hinton Agar (MHA) were solidified 
in the plates over slanted supports to provide inclined 
layers (30o) of culture medium, thus obtaining different 
thicknesses of medium. Second layers of MHA (10 mL) 
containing 106 colony-forming units per milliliter 
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(CFU/mL) of one of the yeast suspensions mixed with one 
of the antibacterials were added over the inclined layers 
and allowed to solidify to form flat surfaces. The plates 
were incubated at 35 °C for two days. The concentration 
of each antibacterial was therefore dependent on the 
thickness of the medium and the diffusion rate of the 
antibacterial.
The colonies which grew in the three regions 
of the antibacterial plates (high, intermediate and low 
concentration) were collected and tested for susceptibility 
to fluconazole and voriconazole, as described by CLSI, 
and for biofilm formation as described by Shin et al., 
(2002).
A confirmatory test was carried out by mixing all 
the antibacterials at a fixed concentration and performing 
susceptibility tests against fluconazole and voriconazole 
for all of the yeasts.
Biofilm formation
To test for the formation of biofilms, suspensions 
of the yeast isolates, both treated and non-treated with 
antibacterials, were adjusted to a concentration of 
3.7 x 107 CFU/mL and 20 μL of each suspension was added 
to 96-well polystyrene microplates containing 180 μL of 
Sabouraud Dextrose Broth (SDB) with glucose at a final 
concentration of 8%. The microplates were incubated at 
35 ºC for 24 h and the transmittance (%T) of each well 
was measured on an ASYS Expert Plus microplate reader 
at a wavelength of 405 nm. Wells containing only SDB 
without yeast suspensions were used as a negative control. 
The degree of biofilm production was measured according 
to Shin et al., 2002.
RESULTS AND DISCUSSION
C. tropicalis,  C. glabrata,  C. albicans,  C. 
parapsilosis and C. guilhermound, previously isolated 
from CVC colonizations, were used to determine the 
influence of antibacterials on antifungal activity. All of the 
yeasts were susceptible to fluconazole and voriconazole, 
MIC ≤ 8 µg/mL and MIC ≤ 1µg/mL, respectively, while 
the highest MIC value (8 µg/mL) was for fluconazole 
against C. glabrata. For all of the yeasts tested, in vitro 
susceptibility to fluconazole and voriconazole after prior 
exposure to antibacterials did not differ significantly 
to that of the non-treated control groups (Table I). The 
additional susceptibility test, in which the antibacterials 
and antifungals were mixed together at the same 
time, produced the same results as those found in the 
antibacterial pre-treatment tests.
Many studies have emphasized that antibacterials 
induce a high risk of candidemia (Lin et al., 2005). 
However, no studies have confirmed the lack of effect 
of antibacterials on antifungal drugs against Candida 
spp. The present research is the first study to have 
investigated possible interactions between cell-wall 
targeted antibacterials and fluconazole or voriconazole 
used against Candida spp.
Several studies have reported that prior treatment 
with antibacterials and fluconazole is a high-risk factor 
for candidemia and can induce resistant non-albicans 
TABLE I – In vitro susceptibility test with voriconazole and fluconazole for Candida species pre-treated with cell-wall targeted 
antibacterials
Antifungals Antibacterials
MIC (µg/mL) values for Candida
tropicalis glabrata guilliermondii albicans parapsilosis
1 2 1 ATCC
Fluconazole
Non-treated Control 0.5 8 0.5 0.25 0.125 0.5 2
V 0.25 8 1 0.25 0.125 0.5 2
PT 0.5 8 0.5 0.25 0.125 0.5 2
M 0.5 8 0.5 0.25 0.125 0.5 1
C 0.25 8 0.5 0.25 0.125 0.5 1
Voriconazole
Non-treated Control 0.03 0.5 0.03 0.03 0.03 0.03 0.06
V 0.03 0.5 0.03 0.03 0.03 0.03 0.03
PT 0.03 0.25 0.03 0.03 0.03 0.03 0.03
M 0.03 0.5 0.03 0.03 0.03 0.03 0.06
C 0.03 0.5 0.03 0.03 0.03 0.03 0.03
Minimal Inhibitory Concentration (MIC); Vancomycin(V); Piperacillin-tazobactam (PT); Meropenem (M); Cefepime (C).
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Candida (Lin et al., 2005; Playford et al., 2008). This 
increased resistance has been observed with candidemia 
caused by C. glabrata and C. kruzei after prolonged 
treatment with vancomycin and piperacillin-tazobactam 
(Lin et al., 2005). The data from these studies suggests 
that antibacterials may, to some degree, affect antifungal 
activity and induce resistant genes in yeasts, as has been 
observed with rifampicin, doxycycline and tigecycline 
(Vogel et al., 2008).
Rifampicin and tigecycline inhibit the synthesis 
of RNA and proteins, and induce the over expression of 
genes that are resistant to fluconazole (Vogel et al., 2008; 
Oliver et al., 2008). In the vast majority of studies, cell-
wall targeted antibacterials are also included among those 
thought to produce a higher risk of candidemia as they are 
used extensively against nosocomial infections in clinical 
practice.
In fact, based on the mechanism of action of 
cell-wall targeted antibacterials, they are not expected 
to act on the cell walls of yeast since the compositions 
of the cell walls of bacteria and yeast are completely 
different. The critical target of cell-wall antibacterials is 
the peptidoglycan layer of bacteria, whereas the target of 
antifungals is the ergosterol layer of yeast.
The candidemia observed after  prolonged 
antibacterial therapy seems to be more attributable to the 
patient’s general condition after long exposure to infection 
and a selection of resistant microbiota, or secondary to 
chronic renal disease and solid organ transplantation 
(Playford et al., 2008).
Biofilm formation is an important virulence factor 
in fungal infections among ICU patients. Therefore, the 
influence of antibacterials on the ability of the yeast to 
form biofilms was also tested. As can be seen in Figure 1, 
C. albicans showed the greatest capacity to form biofilms 
whereas C. tropicalis showed the lowest, both for treated 
and non-treated samples. In this study, the ability to 
form biofilms was not influenced by the presence of the 
antibacterials, even at high concentrations. This finding 
is important, since biofilms are complex polymicrobial 
associations anchored to abiotic or biotic surfaces, 
embedded in extracellular matrix produced by the biofilms 
themselves, where they interact with each other and the 
environment. One of the main properties of biofilms is 
their capacity to be more resistant to antimicrobial agents 
than planktonic cells (Shin et al., 2002).
These results demonstrate that cell-wall targeted 
antibacterials do not affect the biofilm-forming capacity 
FIGURE 1 – Capacity of Candida species to form biofilm after treatment with antibacterials.
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of Candida spp. Based on these results, it can be 
concluded that fungemia caused by Candida spp. is not 
directly influenced by the presence of cell-wall targeted 
antibacterials.
One limitation of this study is that the gene 
expression of Candida species treated with antibacterials 
was not explored. Nevertheless, this study reports a 
negative result which, from a clinical point of view, 
is important because it removes speculation about the 
possibility that cell-wall targeted antibacterials can induce 
candidemia by interfering with the antifungal activity of 
fluconazole and voriconazole.
Another speculative argument for antibacterials 
causing candidemia is that cell-wall targeted antibacterials 
may indirectly induce candidemia by potentiating 
host-directed inflammatory responses against invasive 
bacterial pathogens by releasing pro-inflammatory 
cell-wall components and intracellular toxins following 
bacteriolysis. This effect may exacerbate the inflammatory 
reactions damaging the host cell and tissues, worsening 
the patient’s condition. However this same effect has not 
been observed with antibacterials such as macrolides, 
fluoroquinolones and tetracyclines, as these prevent the 
release of pro-inflammatory toxins of Gram positive and 
Gram-negative bacteria and also inhibit other virulence 
factors working against the excessive production of 
several potent inflammatory mediators (Anderson et al., 
2010). This difference in the mechanism of action of these 
classes of antibacterials may explain, in part, why all 
epidemiological risk factors point to the cell-wall targeted 
antibacterials and not to the protein-synthesis targeted 
antibacterials.
This study corroborates the results found by Playford 
et al.,(2008), who claimed that there was no correlation 
between antibacterial drugs exposure and infection 
by Candida spp. Using data from a large surveillance 
program, prior systemic antifungal exposure, prior 
gastrointestinal surgery, increasing age, and intravenous 
drug use were independently significant risk factors 
associated with non-candida and fluconazole-resistant 
Candida spp among ICU patients with candidemia, while 
pre-treatment with antibacterials were not significant.
CONCLUSIONS
In conclusion, this study proved that cell-wall 
targeted antibacterials do not affect Candida spp. growth 
and biofilm formation, and rejects the hypothesis that these 
antibacterials interact with antifungals to decrease their 
antifungal activity akin to protein-biosynthesis targeted 
antibacterials.
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